Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed/refractory myeloma patients treated with teclistamab: Implications for outpatient step‐up dosing
Charlotte L. B. M. Korst,
Kaz Groen,
Patricia W. C. Bosman,
Fleur van derValk,
Christie P. M. Verkleij,
Sandy Kruyswijk,
Maaike E. M. deRuijter,
Dianne M. Heijink,
Maria T. Kuipers,
Sonja Zweegman,
Niels W. C. J. van deDonk
Affiliations
Charlotte L. B. M. Korst
Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands
Kaz Groen
Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands
Patricia W. C. Bosman
Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands
Fleur van derValk
Department of Hematology Onze Lieve Vrouwe Gasthuis Amsterdam The Netherlands
Christie P. M. Verkleij
Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands
Sandy Kruyswijk
Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands
Maaike E. M. deRuijter
Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands
Dianne M. Heijink
Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands
Maria T. Kuipers
Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands
Sonja Zweegman
Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands
Niels W. C. J. van deDonk
Department of Hematology, Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands
